RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai Henlius Biotech boosted its cash level by selling 55.4 million shares to bring in $192.5 million. Shanghai Helius, a joint venture formed by Henlius Biotech and Shanghai Fosun Pharma in 2009, is developing a portfolio of biosimilars, bio-betters and novel biotech drugs. Fosun contributed $50 million to the fundraising, giving it a 62% majority stake in Shanghai Henlius after the offering. Henlius says it has submitted eight INDs to the CFDA with thirteen indications. Its two lead drugs have started Phase III trials. More details….
Source: China Biotoday
